Professor Robert Hawkins MA MB BS PhD FRCP

2011

• Cheadle EJ, Rothwell DG, Bridgeman JS, Sheard VE, Hawkins RE, Gilham DE. (2011). Ligation of CD2 co-stimulatory receptor enhances IL-2 production from first generation chimeric antigen receptor T cells. Gene Ther, eScholarID:152434
• Elkord E, Sharma S, Burt DJ, Hawkins RE. (2011). Expanded subpopulation of FoxP3(+) T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clin Immunol, 138(1), 218-222. eScholarID:152432
• Gore ME, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, Lee SH, Carteni G, Nieto A, Yuan J, Szczylik C. (2011). Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer, 104(3), 399-406. eScholarID:152426
• Grunwald V, Karakewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I: on behalf of the REACT study Group. (2011). An international expanded access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer, eScholarID:152433
• Harrop R, Shingler WH, McDonald M, trasurer P, Amato RJ, Hawkins RE, Kaufmann HL, de Belin J, Kelleher M, Goonewardena M, Naylor S. (2011). MVA-5T4 induced immunoresponses are an early marker of efficacy in renal canceer patients. Cancer Immunol Immunother, 60(6), 829-837. eScholarID:152430 | DOI:10.1007/s00262-011-0993-7
• Shablak A, O'Dwyer J, Hawkins R, Board R. (2011). Management of a new isolated metastasis during sunitinib treatment in renal cell carcinoma patients: a lesson from two cases. Urol Int, 86(2), 245-248. eScholarID:152427 | DOI:10.1159/000321908
• Shablak A, Sikand K, Shanks JH, Thistlethwaite F, Spencer-Shaw A, Hawkins RE. (2011). High dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother, 34(1), 107-112. eScholarID:152429 | DOI:10.1097/CJI.0b013e3181fb659f

2010

• Amato RJ, Hawkins R, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, McDonald M, Eastty S, Shingler WH, Debelin J, Goonewardena M, Naylor S, Harrop R. (2010). Vaccination of metastatic renal cancer patients with MVA-5T4: A randomised double blind, placebo controlled phase III study. Clin Cancer Res, 16(22), 5539-5547. eScholarID:152424 | DOI:10.1158/1078-0432.CCR-10-2082
• Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE. (2010). The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol, 184(12), 6938-6949. eScholarID:152419 | DOI:10.4049/jimmunol.0901766
• Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE. (2010). Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther, 10(2), 77-90. eScholarID:152417 | DOI:10.2174/156652310791111001
• Buning H, Uckert W, Cickutek K, Hawkins RE, Abken H. (2010). Do CARs need a driver license? Adoptove cell therapy with chimeric antigen receptor-redirected T cells caused serious adverse events. Hum Gene Ther, 21(9), 1039-1042. eScholarID:152420 | DOI:10.1089/hum.2010.131
• Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE. (2010). Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumour acitivity of CD19 specific engineered T cell. J Immunol, 184(4), 1885-1896. eScholarID:149948 | DOI:10.4049/jimmunol.0901440
• Dangoor A, Lorigan P, Keilhoz U, Schadendorf D, Harris A, Ottensmeir C, Smyth J, Hoffmann K, Anderson R, Cripps M, Schneider J, Hawkins R. (2010). Clinical and immunological responses in metastatic meanoma patients vaccinated with a high dose poly-epitope vaccine. Cancer Immunol Immunother, CII 59.6, 863-873. eScholarID:149932
• El-Hariry I, Powles T, Lau MR, Sternberg CN, Ravaud A, von der Maase H, Zantl, N, Harper P, Rolland F, Audhuy B, Barthel F, Machiels JP, Patel P, Kreuser ED, Hawkins RE. (2010). Amplification of epidermal growth factor receptor gene in renal cell carcinoma. Eur J Cancer, eScholarID:149936
• Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE. (2010). T regulatory cells in cancer: recent advances in therapeutics potential. Expert Opin Biol Ther, 10(11), 1573-1586. eScholarID:152425 | DOI:10.1517/14712598.2010.529126
• Gilham DE, Lie-A-Ling M, Taylor N, Hawkins RE. (2010). Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction of mouse T cells with HIV-1 vectors. J Gene Med, 12(2), 129-136. eScholarID:149923 | DOI:10.1002/jgm.1421
• Hawkins RE, Gilham DE, Debets R, Eshhar Z, Taylor N, Abken H, Schumacher TN, ATTACK Consortium. (2010). Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther, 21(6), 665-672. eScholarID:152418 | DOI:10.1089/hum.2010.086
• Ralph C, Elkord E, Burt DJ, O'Dwyer JF, Austin EB, Stern PL, Hawkins RE, Thistlethwaite FC. (2010). Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and oesophageal adenocarcinoma. Clin cancer Research, 16(5), 1662-1672. eScholarID:152416 | DOI:10.1158/1078-0432.CCR-09-2870
• Rossi JF, Negrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B. (2010). A phase I/II study of siltuximab (CNTO) an anti-interleukin-6 monoclonal antibody in metastatic renal cell cancer. Br J Cancer, 38(6), 1154-1162. eScholarID:152423
• Rothwell DG, Crossley R, Bridgeman JS, Sheard V, Zhang Y, Sharp T, Hawkins RE, Gilham D, McKay TR. (2010). Functional expression of secreted proteins from a bicistronic retroviral cassette based on FMDV 2A can be position dependent. Hum Gene Ther, 21(11), 1631-1637. eScholarID:152421 | DOI:10.1089/hum.2009.197
• Sternberg CN, Davis ID, Mardiak J, Szcylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomised phase III trial. J Clin Oncol, 28(6), 1061-1068. eScholarID:149955 | DOI:10.1200/JCO.2009.23.9764
• Waddington SN, Crossley R, Sheard V, Howe SJ, Buckley SM, Coughlan L, Gilham DE, Hawkins RE, McKay TR. (2010). Gene delivery of a mutant TGFbeta3 reduces markers of scar tissue formation after cutaneous wounding. Mol Ther, 38(6), 1489-1493. eScholarID:152422

2009

• Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE. (2009). Eradication of Established B-cell Lymphoma by CD19-specific Murine T Cells is Dependent on Host Lymphopenic Environment and can be Mediated by CD4+ and CD8+ T Cells. J Immunother, eScholarID:1d32526 | DOI:10.1097/CJI.0b013e318194a921
• Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE. (2009). Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. J Immunother, 32(3), 207-218. eScholarID:149908 | DOI:10.1097/CJI.0b013e318194a921
• Elkord E, Dangoor A, Burt DJ, Southgate TD, Daayana S, Harrop R, Drijfhout JW, Sherlock D, Hawkins RE, Stern PL. (2009). Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Epub, 58(10), 1657-1667. eScholarID:149889
• Elkord E, Shablak A, Stern PL, Hawkins RE. (2009). 5T4 as a target for immunotherapy in renal cell carcinoma. Expert Rev Anticancer Ther, 9(12), 1705-1709. eScholarID:149919 | DOI:10.1586/era.09.152
• Hawkins RE, Macdermott C, Shablak A, Hamer C, Thistlethwaite F, Drury NL, Chikoti P, Shingler W, Naylor S, Harrop R. (2009). Vaccination of patients with metastatic renal cancer with modified vaccina Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother, 32(4), 424-429. eScholarID:149915 | DOI:10.1097/CJI.0b013e31819d297e
• Hawkins, RE, Macdermott, C, Shablak, A, Hamer, C, Thistlethwaite, F, Drury, N, Chikoti, P, Shingler, W, Naylor, S, Harrop, R. (2009). Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother, 32( 4), eScholarID:1d32656 | DOI:10.1097/CJI.0b013e31819d297e

2008

• Alain Ravaud, Robert Hawkins, Jason P. Gardner, Hans von der Maase, Niko Zantl, Peter Harper, Frederic Rolland, Bruno Audhuy, Jean-Pascal Machiels, Frank Petavy, Martin Gore, Patrick Schoffski, and Iman El-Hariry. (2008). Phase III Clinical Trial of Lapatinib Compared With Hormone Therapy in Patients With Advanced Renal Cell Carcinoma. J Clin Oncol, 26(14), 2285-2291. eScholarID:153477 | DOI:10.1200/JCO.2007.14.5029
• Cheadle EJ, Gilham DE, Hawkins RE. (2008). The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br J Haematol, eScholarID:1d32096 | DOI:10.1111/j.1365-2141.2008.07145.x
• Jones R, Hawkins RE, Eatock M, Ferry D, Eskens F, Wilke H, Evans T. (2008). A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol, 61( 3), 435-41. eScholarID:1d31719

2007

• Cheadle EJ, Riyad K, Subar D, Rothwell DG, Ashton G, Batha H, Sherlock D, Hawkins RE, Gilham DE. (2007). Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin Cancer Res, 13( 19), 5719-28. eScholarID:1d31758
• Elkord E, Burt DJ, Drijfhout JW, Hawkins RE, Stern PL. (2007). CD4(+) T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25(+) T cells. Cancer Immunol Immunother, eScholarID:1d31718
• Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, Hawkins RE. (2007). Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother, eScholarID:1d31370
• Harrop, R, Drury, N, Shingler, W, Chikoti, P, Redchenko, I, Carroll, M, Kingsman, S, Naylor, S, Griffiths, R, Steven, N, Hawkins, RE. (2007). Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother, eScholarID:1d31723
• Shaw, D, Connolly, N, Patel, P, Kilany, S, Hedlund, G, Nordle, O, Forsberg, G, Zweit, J, Stern, P, Hawkins, RE. (2007). A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer, 96( 4), 567-74. eScholarID:1d31622
• Thistlethwaite F, Gilham D, Hawkins RE. (2007). Cellular therapy of cancer symposium December 2nd-3rd 2006 Manchester, UK. Cancer Immunol Immunother, 56( 6), 939-42. eScholarID:1d31417
• Thistlethwaite, F, Elkord, E, Griffiths, R, Burt, D, Shablak, A, Campbell, J, Gilham, D, Austin, E, Stern, P, Hawkins, RE. (2007). Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother, eScholarID:1d31881

2006

• Board RE, Thistlethwaite FC, Hawkins RE. (2006). Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev, eScholarID:1d30946
• Chong, G, Bhatnagar, A, Cunningham, D, Cosgriff, T, Harper, P, Steward, W, Bridgewater, J, Moore, M, Cassidy, J, Coleman, R, Coxon, F, Redfern, C, Jones, J, Hawkins, RE, Northfelt, D, Sreedharan, S, Valone, F, Carmichael, J. (2006). Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol, 17( 3), 437-42. eScholarID:1d30387
• Dangoor A, Thistlethwaite F, Hawkins RE. (2006). Cancer vaccines: a clinical perspective. Br J Hosp Med (Lond), 67( 7), 365-9. eScholarID:1d31010
• Harrop, R, Connolly, N, Redchenko, I, Valle, J, Saunders, M, Ryan, M, Myers, K, Drury, N, Kingsman, S, Hawkins, RE, Carroll, M. (2006). Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res, 12( 11 Pt 1), 3416-24. eScholarID:1d31744
• Jiang H, Gilham D, Mulryan K, Kirillova N, Hawkins RE, Stern PL. (2006). Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol, 177( 7), 4288-98. eScholarID:1d14859
• Redchenko I, Harrop R, Ryan M, Hawkins RE, Carroll M. (2006). Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology, 118( 1), 50-7. eScholarID:1d31724
• Smyth, L, Elkord, E, Taher, T, Jiang, H, Burt, D, Clayton, A, van Veelen, P, de Ru, A, Ossendorp, F, Melief, C, Drijfhout, J, Dermime, S, Hawkins, RE, Stern, PL. (2006). CD8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer, 119( 7), 1638-47. eScholarID:1d30909

2005

• Annabi, B, Bouzeghrane, M, Currie, J, Hawkins, RE, Dulude, H, Daigneault, L, Ruiz, M, Wisniewski, J, Garde, S, Rabbani, S, Panchal, C, Wu, J, Béliveau, R. (2005). A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis. Clin Exp Metastasis, 22(5), 429-439. eScholarID:1d30157
• Armstrong A, Cheadle EJ, Hawkins RE. (2005). Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin. BioDrugs, 19( 5), 289-97. eScholarID:1d29874
• Cheadle EJ, Gilham DE, Thistlethwaite FC, Radford JA, Hawkins RE. (2005). Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol, 129( 3), 322-32. eScholarID:1d29482
• Griffiths R, Gilham DE, Dangoor A, Ramani V, Clarke N, Stern PL, Hawkins RE. (2005). Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer, 93( 6), 670-7. eScholarID:1d28868
• Guest, R, Hawkins, RE, Kirillova, N, Cheadle, EJ, Arnold, J, O'Neill, A, Irlam, J, Chester, K, Kemshead, J, Shaw, D, Embleton, M, Stern, PL, Gilham, DE. (2005). The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother, 28( 3), 203-11. eScholarID:1d30720
• Hawkins, RE, Daigneault, L, Cowan, R, Griffiths, R, Panchal, C, Armstrong, A, Fenemore, J, Irvine, A, Sereda, K, Dulude, H. (2005). Safety and Tolerability of PCK3145, a Synthetic Peptide Derived from Prostate Secretory Protein 94 (PSP94) in Metastatic Hormone-Refractory Prostate Cancer. Clin Prostate Cancer, 4( 2), 91-9. eScholarID:1d31098
• Lapointe, R, Létourneau, R, Steward, W, Hawkins, RE, Batist, G, Vincent, M, Whittom, R, Eatock, M, Jolivet, J, Moore, M. (2005). Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors. Ann Oncol, 16( 2), 289-93. eScholarID:1d29779
• Mansoor W, Gilham DE, Thistlethwaite FC, Hawkins RE. (2005). Engineering T cells for cancer therapy. Br J Cancer, 93( 10), 1085-91. eScholarID:1d30054
• Ramage, J, Davies, A, Ardill, J, Bax, N, Caplin, M, Grossman, A, Hawkins, RE, McNicol, A, Reed, N, Sutton, R, Thakker, R, Aylwin, S, Breen, D, Britton, K, Buchanan, K, Corrie, P, Gillams, A, Lewington, V, McCance, D, Meeran, K, Watkinson, A, NULL. (2005). Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut, 54 Suppl 4, iv1-16. eScholarID:1d30829
• Rao S, Cunningham D, Hawkins RE, Hill M, Smith D, Daniel F, Ross P, Oates J, Norman A. (2005). Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer, 92( 9), 1650-4. eScholarID:1d29778
• Smith, C, Dunbar, P, Mirza, F, Palmowski, M, Shepherd, D, Gilbert, S, Coulie, P, Schneider, J, Hoffman, E, Hawkins, RE, Harris, A, Cerundolo, V. (2005). Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer, 113( 2), 259-66. eScholarID:1d31507
• Tew S, Li Y, Pothacharoen P, Tweats L, Hawkins RE, Hardingham T. (2005). Retroviral transduction with SOX9 enhances re-expression of the chondrocyte phenotype in passaged osteoarthritic human articular chondrocytes. Osteoarthritis Cartilage, 13( 1), 80-9. eScholarID:1d29821
• Thistlethwaite FC, Mansoor W, Gilham DE, Hawkins RE. (2005). Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy. Curr Opin Mol Ther, 7( 1), 48-55. eScholarID:1d29690
• Whitworth, M, Sheen, A, Rosa, D, Duff, S, Ryder, D, Burumdayal, A, Wiener, K, Hawkins, R, Hawkins, RE, Saunders, M, Valle, JW, Sherlock, D, Jayson, G. (2005). Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. J Cancer Res Clin Oncol, 1-4. eScholarID:1d29650

2004

• Armstrong A, Dermime S, Mulryan K, Stern PL, Bhattacharyya T, Hawkins RE. (2004). Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma. J Immunother, 27( 3), 227-31. eScholarID:1d9257 | DOI:10.1097/00002371-200405000-00007
• EK Meziane, T Bhattacharyya, Armstrong A, C Qian, Hawkins RE, Stern PL, Dermime S. (2004). Vaccination with B lymphoma cell modified with adenovirus encoding CD40L and or IL2 for tumour therapy. International Journal Of Cancer, 910-920. eScholarID:1d26113
• Li Y, Tew S, Russell A, Gonzalez K, Hardingham T, Hawkins RE. (2004). Transduction of passaged human articular chondrocytes with adenoviral, retroviral, and lentiviral vectors and the effects of enhanced expression of SOX9. Tissue Eng, 10( 3-4), 575-84. eScholarID:1d29822
• Li Y, Tew SR, Russell A, K Gonzales, Hardingham TE, Hawkins RE. (2004). Transduction of passaged human articular chondrocytes with adenoviral, retroviral and lentiviral vectors and the effects of enhanced expression of SOX9. Tissue Engineering, 3-4, 575-584. eScholarID:1d9264
• Meziane E, Bhattacharyya T, Armstrong A, Qian C, Hawkins RE, Stern PL, Dermime S. (2004). Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer, 111( 6), 910-20. eScholarID:1d28770
• Pedley R, Sharma S, Hawkins RE, Chester K. (2004). Antibody-directed enzyme-prodrug therapy. Methods Mol Med, 90, 491-514. eScholarID:1d30056

2003

• Sheen A, Irlam J, Kirillova N, Guest R, Sherlock D, Hawkins RE, Gilham DE. (2003). Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Dis Colon Rectum, 46( 6), 793-804. eScholarID:1d28988
• Sheen A, Sherlock D, Irlam J, Hawkins RE, Gilham DE. (2003). T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br J Cancer, 88( 7), 1119-27. eScholarID:1d29369
• Sheen AJ, Irlam JJ, Kirillova N, Guest RD, Sherlock DJ, Hawkins RE, Gilham DE. (2003). Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Diseases Of The Colon And Rectum, 46(6), 793-804. eScholarID:1d33539
• Sheen AJ, Sherlock DJ, Irlam JJ, Hawkins RE, Gilham DE. (2003). T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. British Journal Of Cancer, 88(7), 1119-27. eScholarID:1d33535

2002

• Armstrong A, Dermime S, Allinson C, Bhattacharyya T, Mulryan K, Gonzalez K, Stern PL, Hawkins RE. (2002). Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol, 168( 8), 3983-91. eScholarID:1d9261
• Armstrong A, Dermime S, Chris Allinson, Tapan Battacharrya, Kate Mulryan, Karin Gonzales, Stern PL, Hawkins RE. (2002). Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. Journal of Immunology, (168) 8, 3983-91.. eScholarID:1d1971
• Bramhall SR Hallissey MT Whiting J Scholefield J Tierney G Stuart RC, McCulloch P Maughan TBrown PD Baillet M Fielding JWL, Hawkins RE. (2002). Marimastat as Maintenance Therapy for Patients with Advanced Gastric and Gastro-oesophageal Cancer: A Randomised Trial. British Journal of Cancer, (86)12, 1864-70.. eScholarID:1d1967
• Dermime S, Armstrong A, Hawkins RE, Stern PL. (2002). Cancer vaccines and immunotherapy. British Medical Bulletin, (62)1, 149-62.. eScholarID:1d1966
• Eaton D, Gilham DE, Allison O'Neill, Hawkins RE. (2002). Retroviral transduction of human peripheral blood lymphocytes with bcl-x(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Therapy, (9)8, 527-35. eScholarID:1d1964
• Eaton D, Gilham DE, O'Neill A, Hawkins RE. (2002). Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Ther, 9( 8), 527-35. eScholarID:1d9259 | DOI:10.1038/sj.gt.3301685
• Eaton D, Hawkins RE. (2002). Cimetidine in colorectal cancer--are the effects immunological or adhesion-mediated?. British Journal of Cancer, (86)2, 159-60.. eScholarID:1d1969
• Gilham DE, Allison O'Neill, Hughes C, Guest RD, Kirillova N, Margaret Lehane, Hawkins RE. (2002). Primary Polyclonal Human T Lymphocytes Targeted to Carcino-Embryonic Antigens and Neural Cell Adhesion Molecule Tumor Antigens by CD3-Based Chimeric Immune Receptors. Journal of Immunotherapy, 25(2), 139-151. eScholarID:1d23481
• Gilham DE, O'Neil A, Hughes C, Guest R, Kirillova N, Lehane M, Hawkins RE. (2002). Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother, 25( 2), 139-51. eScholarID:1d28732
• P K Dehal, Embleton J, J Kempshead, Hawkins RE. (2002). Targeted cytokine delivery to neuroblastoma. Biochem Soc Trans, 30(4), 518-20. eScholarID:1d1962

2001

• Armstrong A, Hawkins RE. (2001). Vaccines in oncology: background and clinical potential. British Journal of Radiologists, 74(887), 991-1002. eScholarID:1d1973
• Miller DW Jerome V Zuzarte M Watkins SJ Muller R Kontermann RE, Nettelbeck DM, Hawkins RE. (2001). Targeting of Adenovirus to Endothelial Cells by a Bispecific Single-Chain Diabody Directed against the Adenovirus Fiber Knob Domain and Human Endoglin (CD105). Molecular Therapy, 3(6), 882-91.. eScholarID:1d1974

2000

• Nicklin SA White SJ Watkins SJ Baker AH, Hawkins RE. (2000). Selective targeting of gene transfer to vascular endothelial cells using peptide isolated by phage display. Circulation, 102(2):, 231-7.. eScholarID:1d1975

1999

• Holliger P Manzke O Span M, Fleischmann B Qinghua L Wolf J Diehl V Cochet O Winter G Bohlen H, Hawkins RE. (1999). Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Research, 59(12), 2909-2916. eScholarID:1d1976